SLDB vs SRPT
SLDB: A clinical-stage biotechnology company developing gene therapies to treat rare, life-threatening neuromuscular and cardiac diseases. SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy.
Side-by-side fundamentals
| Metric | SLDB | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $6.82 | $18.21 | |
| Market cap | $731M | $1.9B | |
| Net margin | -1062.3% | -32.5% | SRPT higher |
| Operating margin | -1315.2% | -31.8% | SRPT higher |
| ROE FY2025, SEC XBRL | -96.8% | -62.5% | SRPT higher |
| ROA FY2025, SEC XBRL | -75.0% | -21.3% | SRPT higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.55 | SLDB lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | -20.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +33.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.68 | 1.56 | |
| 1-year return as of 2026-10-08 close | +8.1% | -22.1% | SLDB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.